You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.
According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.
Technology Review reports synthetic biologists are developing an attenuated SARS-CoV-2 to use in a vaccine.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.